Piramal Life Sciences, a research and development (R&D) arm of Piramal Group is investing Rs 200 crore in the next two year’s period for its ambitious programme to discover and develop new chemical entitities (NCEs) and Novel Drug Delivery Systems (NDDSs), a top company official said here.

“Piramal Life Sciences has embarked upon an ambitious programme to discover and develop new chemical entitities (NCEs) and Novel Drug Delivery Systems (NDDSs) in select therapeutic areas, including cancer, inflammation, diabetes/metabolic disorders and infectious diseases with a pipeline of 14 molecules in different phases of development,” Piramal Healthcare Director, Swati Piramal told PTI here.

Piramal Life Sciences is investing Rs 100 crore every year in R&D and will invest Rs 200 crore in the next two year’s period, Piramal said.

Piramal Healthcare launches around 10-12 products every year.

“Last year we were leading company launching new products. We don’t do generics so we are looking at scientific products only where we have some innovation, which can sell as breakthrough products,” Piramal said.

Piramal Healthcare is currently ranked fourth in the Indian market with a diverse product portfolio spanning 14 therapeutic areas.

The company also has one of the largest custom manufacturing companies with a global footprint of assets across North America, Europe and Asia.

“Piramal Healthcare pharma hopes to maintain 30 per cent growth. During the Q4FY09, the company grew by 25 per cent in domestic pharma market,” Piramal said.

Piramal Healthcare’s pharma solution division carrying out custom manufacturing for global innovator pharmaceutical companies since 2003. The group has invested about Rs 450 crore in Indian and Rs 338 crore in international assets to scale-up this business during last six years period.

Charting roadmap for the future, pharma solution division aims to cater to end-patient oriented solutions with formulations and packaging innovations.

The approach adopted is to keep the cost competitiveness of its Indian assets at the core, and then build a global outsourcing business around these assets.

Piramal Group’s diagnostic services division offers a full range of clinical diagnostic services. It is the largest player in this field and operates 90 centres spread across 57 locations in India.

Piramal Diagnostic Services serves all segments in this business and is the leader in each.

The aim of diagnostic services is to be present, in the next two years, in all cities with a population of one million or more, Piramal said.

source: Business-Standard

Tags: bse india, hot stocks, india market, nse india, primal, sensex india, share market, small cap stocks

Similar Posts:

• Nicholas Piramal reports revenues grow 13% to Rs 7.3bn
• Buy Piramal Healthcare, target of Rs 358: Sharekhan
• Satyam sets-up Life Sciences Center of Excellence
• Glaxo in talks to buy Piramal Healthcare: report
• Piramal Health looks at buyout for expansion